Using muscle homing peptide CyPep10 to deliver phosphorodiamidate morpholino oligomers in the mdx mouse

The severe muscle wasting disorder Duchenne muscular dystrophy (DMD) is characterized by the absence of dystrophin, a protein that is essential for muscle stability. Restoring this protein has therapeutic potential. Antisense oligonucleotides (ASOs), designed to target and skip exons, can restore the reading frame that is disrupted in these patients, enabling the production of partially functional dystrophin. Achieving optimal dystrophin restoration remains challenging due to limited delivery and cellular uptake. Muscle homing peptides conjugated to ASOs are a way to achieve this. Previously, CyPep10 (CP10) has been used to significantly increase exon skipping efficiency for the 2’-O-methyl phosphorothioate (2OMePS) chemistry in the mdx mouse model for DMD. Here, we explore the effect of using peptide CP10 as a conjugate to phosphorodiamidate morpholino oligomer (PMOs) ASOs to improve muscle delivery, thereby hoping to achieve increased treatment efficiency. Overall, we confirmed the homing ability of CP10 and observed significantly increased muscle tissue concentration levels of PMO when CP10 was conjugated. This did not lead to increased levels of exon skipping or dystrophin restoration. Conjugating both a cell penetrating peptide (CPP) and CP10 to a PMO showed that increased exon skipping efficiency can be achieved, to a slightly higher extent than CPP-PMO treatment.